<Document>
	<CASIS.DOCNO>PD025950</CASIS.DOCNO>
	<CASIS.UPD>20160229</CASIS.UPD>
	<SO>T&amp;F Informa UK Ltd, London</SO>
	<CASIS.CN>
		<DrugNameData>
			<DrugName isPrimaryDrugName="false">AR-C124910XX</DrugName>
			<DrugName isPrimaryDrugName="false">AR-C126532</DrugName>
			<DrugName isPrimaryDrugName="false">AR-C126532 (orodispersible
				tablet)</DrugName>
			<DrugName isPrimaryDrugName="false">AR-C126532XX</DrugName>
			<DrugName isPrimaryDrugName="false">AR-C126532XX (orodispersible
				tablet)</DrugName>
			<DrugName isPrimaryDrugName="false">Axcer</DrugName>
			<DrugName isPrimaryDrugName="false">AZD-6140</DrugName>
			<DrugName isPrimaryDrugName="false">AZD-6140 (orodispersible tablet)
			</DrugName>
			<DrugName isPrimaryDrugName="false">AZD6140</DrugName>
			<DrugName isPrimaryDrugName="false">AZD6140 (orodispersible tablet)
			</DrugName>
			<DrugName isPrimaryDrugName="false">Brilinta</DrugName>
			<DrugName isPrimaryDrugName="false">Brilique</DrugName>
			<DrugName isPrimaryDrugName="false">Brillique</DrugName>
			<DrugName isPrimaryDrugName="false">Possia</DrugName>
			<DrugName isPrimaryDrugName="true">ticagrelor</DrugName>
			<DrugName isPrimaryDrugName="false">ticagrelor (orodispersible
				tablet)</DrugName>
			<DrugName isPrimaryDrugName="false">ticagrelor ODT</DrugName>
		</DrugNameData>
		<ChemicalName>1,2-Cyclopentanediol,
			3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-,
			(1S,2S,3R,5S)-</ChemicalName>
	</CASIS.CN>
	<CASIS.RN>
		<CASNumber>274693-27-5</CASNumber>
	</CASIS.RN>
	<NCE>Yes</NCE>
	<Origin>Chemical, synthetic</Origin>
	<MF>C23H28F2N6O4S</MF>
	<MW>522.57</MW>
	<CASIS.TX>
		<Overview>Ticagrelor (AZD-6140) is an orally-active reversible P2Y12
			ADP purinoreceptor antagonist, developed by AstraZeneca for the
			treatment of arterial thrombosis (1st Half Res, AstraZeneca, 2001;
			Company pipeline, AstraZeneca, 22 Jul 2004; USAN Web Page, 21 Aug
			2007). It is a non-prodrug, non-thienopyridine belonging to the
			cyclo-pentyl-triazolo-pyrimidine (CPTP) class, that has a rapid onset
			of action and shows reversible binding to receptors (Ann Bus Rev,
			AstraZeneca, 7 Nov 2002 &amp; 6 Oct 2004). It is expected that
			coronary disease patients treated with ticagrelor could be operated
			on within 24hr of treatment, vs a delay of 5 days for those treated
			with clopidogrel hydrogen sulfate (Analysts&apos; presentation,
			AstraZeneca, 2 Feb 2006).</Overview>
		<Marketing>Approvals ^________________^Acute coronary syndrome;
			Angina, unstable; Infarction, myocardial; Thrombosis,
			arterial^Austria (2011); launched as Brilique (Company presentation,
			AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Australia
			(2012); as Brilique (Press release, AstraZeneca, 20 Jul 2011,
			http://www.astrazeneca.com/Media/Press-releases/Article/20110720-fda-approves-brilinta-us;
			Company presentation, AstraZeneca, 30 Oct 2013, Slide 19,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DPresentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285660606247&amp;ssbinary=true).
			^Belgium (Company presentation, AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Brazil
			(2011); launched as Brilique (Company presentation, AstraZeneca, 9
			Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Bulgaria;
			approved as Brilique (Company presentation, AstraZeneca, 9 Sep 2011,
			page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Canada
			(2011); launched as Brilique (Company presentation, AstraZeneca, 9
			Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Czech
			Republic; approved as Brilique (Company presentation, AstraZeneca, 9
			Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Denmark
			(2011); launched as Brilique (Company presentation, AstraZeneca, 27
			Jan 2011, p20 of PDF,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DPresentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285616560306&amp;ssbinary=true).^Estonia
			(2011) (Company presentation, AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).
			^EU; approved as Brilique to be co-administered with ASA for
			prevention of atherothrombotic events in adult patients with ACS
			(unstable angina, NSTEMI or STEMI); including patients managed
			medically, and those who are managed with percutaneous coronary
			intervention (PCI) or coronary artery by-pass grafting (CABG) (Press
			release, EMA, 23 Sep 2010,
			http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002303/WC500097029.pdf;
			Press release, AstraZeneca, 6 Dec 2010,
			http://www.astrazeneca.com/Media/Press-releases/Article/European-Commission-Approves-Brilique).
			Brilique is the approved trade name for use in the EU countries and
			EEA countries (Press release, AstraZeneca, 16 Mar 2010).^Finland
			(2011); launched as Brilique (Company presentation, AstraZeneca, 9
			Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^France
			(2012); launched in Jul 2012 (Q3 2012 Earnings Call,
			AstraZeneca).^Germany (2011); launched as Brilique (Company
			presentation, AstraZeneca, 27 Jan 2011, p20 of PDF,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DPresentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285616560306&amp;ssbinary=true).
			^Greece (2011); launched as Brilique (Company presentation,
			AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Hungary;
			approved as Brilique (Company presentation, AstraZeneca, 9 Sep 2011,
			page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Iceland;
			approved as Brilique (Company presentation, AstraZeneca, 9 Sep 2011,
			page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^India
			(2012); as Brilique for the treatment of acute coronary syndromes
			(ACS) in adult patients (Scrip Intelligence, 19 Oct 2012,
			http://www.scripintelligence.com/business/AstraZeneca-launches-0.94-Brilinta-in-India-336338).
			It is also to be sold as Axcer (Scrip Intelligence, 2 Jun 2015,
			http://www.scripintelligence.com/business/AstraZeneca-unveils-second-brand-play-in-India-358707).^Ireland;
			approved as Brilique (Company presentation, AstraZeneca, 9 Sep 2011,
			page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Italy;
			as Brilique (2nd Qtr &amp; Half Year Res, AstraZeneca, 2012, Slide
			31, http://cache.cantos.com/download/azn-k009/presentation.pdf).
			^Latvia (2011) (Company presentation, AstraZeneca, 9 Sep 2011, page
			49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Lithuania
			(2011) (Company presentation, AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Luxembourg
			(Company presentation, AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Malaysia
			(2011); launched as Brilique (Company presentation, AstraZeneca, 9
			Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Mecedonia
			(Company presentation, AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Netherlands
			(2011); launched as Brilique (Company presentation, AstraZeneca, 9
			Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^New
			Zealand; as Brilique (Company presentation, AstraZeneca, 9 Sep 2011,
			page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Norway
			(2011); launched as Brilique (Company presentation, AstraZeneca, 9
			Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Poland;
			approved as Brilique (Company presentation, AstraZeneca, 9 Sep 2011,
			page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).
			^Portugal (Company presentation, AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Romania;
			approved as Brilique (Company presentation, AstraZeneca, 9 Sep 2011,
			page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Singapore
			(2011) (Company presentation, AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^South
			Korea; approved as Brilinta (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Slovakia;
			approved as Brilique (Company presentation, AstraZeneca, 9 Sep 2011,
			page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Slovenia
			(Company presentation, AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Spain;
			approved as Brilique (Company presentation, AstraZeneca, 9 Sep 2011,
			page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Sweden
			(2011); launched as Brilique (Company presentation, AstraZeneca, 9
			Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Switzerland
			(Company presentation, AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Syria;
			approved as Brilique (Company presentation, AstraZeneca, 9 Sep 2011,
			page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^UK
			(2011); launched as Brilique (MIMS UK New Products, 4 Jan 2011,
			http://www.mims.co.uk/more/NewDrugs/article/1047693/Brilique-novel-alternative-clopidogrel/).
			The UK NICE has published a final draft guidance recommending
			Brilique in combination with aspirin, for upto 12mth in patients with
			ACS (unstable angina, NSTEMI or STEMI) (Scrip Intelligence, 26 Oct
			2011,
			http://www.scripintelligence.com/policyregulation/NICE-gives-clot-busting-Brilique-the-final-OK-322928).^Uruguay;
			approved as Brilique (Company presentation, AstraZeneca, 9 Sep 2011,
			page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^USA
			(2011); launched as Brilinta to reduce the rate of thrombotic
			cardiovascular events in patients with ACS (unstable angina;
			non-ST-elevation myocardial infarction or ST-elevation myocardial
			infarction). It will be available in 90mg tablets to be administered
			with a single 180mg oral loading dose, followed by twice daily 90mg
			maintenance dose (Press release, AstraZeneca, 20 Jul 2011,
			http://www.astrazeneca.com/Media/Press-releases/Article/20110720-fda-approves-brilinta-us;
			Press release, AstraZeneca, 22 Aug 2011,
			http://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&amp;newsId=20110822005750&amp;newsLang=en).
			The US labeling includes a boxed warning stating that aspirin doses
			above 100mg/day decrease the effectiveness of ticagrelor, and should
			be avoided (Company presentation, AstraZeneca, 27 Jul 2011, page 30,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DPresentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285625738292&amp;ssbinary=true;
			Company presentation transcript, AstraZeneca, 27 Jul 2011, p2,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DMartin-Mackay%2C-President-R%26amp%3BD-analyst-script.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285625798831&amp;ssbinary=true).
			The FDA has recomended for use in the management of patients
			undergoing percutaneous coronary intervention (PCI) under revised
			treatment guidelines (Scrip Intelligence, 8 Nov 2011,
			http://www.scripintelligence.com/policyregulation/Class-1-recommendation-for-Brilinta-in-the-US-323380).
			It also has the FDA approval to be crushed and administered in water
			by swallowing or via nasogastric tube in acute coronary syndrome
			patients who are unable to swallow ticagrelor 90mg tablets as whole
			(Press release, 30 Mar 2015, AstraZeneca,
			http://www.astrazeneca-us.com/media/press-releases/Article/20150330-brilinta-receives-approval-for-new-administration).^Acute
			coronary syndrome; Thrombosis, arterial^AstraZeneca^China; as
			Brilinta (Press release, Reuters, 29 Nov 2012,
			http://www.reuters.com/article/2012/11/29/us-astrazeneca-china-idUSBRE8AS0FT20121129).^Acute
			coronary syndrome; Infarction, myocardial^EU (including Iceland,
			Norway and Liechtenstein); as Brilique at a 60mg dose for the
			treatment of patients who have suffered a heart attack at least one
			year prior and are at high risk of developing a further
			atherothrombotic event (Press release, AstraZeneca, 19 Feb 2016,
			https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/Brilique-ticagrelor-approved-in-EU-for-extended-treatment-of-patients-with-history-of-heart-attack-19022016.html).^USA
			(2015); as Brilinta 60mg tablet for patients with a history of heart
			attack beyond the 1st yr and used to reduce the rate of
			cardiovascular death, myocardial infarction (MI) and stroke in
			patients with acute coronary syndrome (ACS) or a history of MI (Press
			release, AstraZeneca, 3 Sep 2015,
			http://www.astrazeneca.com/Media/Press-releases/Article/20150903;
			Press release, AstraZeneca, 29 Sep 2015,
			http://www.businesswire.com/news/home/20150929005612/en/Dose-Brilinta-Pharmacies).^Filings^________________^Acute
			coronary syndrome^China; a filing for use in patients with Type 2
			diabetes and CAD but without previous history of MI or stroke (based
			on results from the THEMIS trial) is expected in 2019 (Company
			pipeline, AstraZeneca, 31 Dec 2013 &amp; 31 Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true;
			Company pipeline, AstraZeneca, 23 Feb 2016,
			https://www.astrazeneca.com/our-science/pipeline.html).^EU; a filing
			for use in patients with Type 2 diabetes and CAD but without previous
			history of MI or stroke (based on results from the THEMIS trial) is
			expected in 2018 (Press release, AstraZeneca, 30 Jul 2015, Page 47,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285696919720&amp;ssbinary=true).
			^Japan; a filing has been submitted for ACS (Scrip Intelligence, 13
			Dec 2013,
			http://www.scripintelligence.com/home/New-launches-provide-platform-for-AstraZenecas-Japanese-growth-348750).
			A filing for use in patients with Type 2 diabetes and CAD but without
			previous history of MI or stroke (based on results from the THEMIS
			trial) is expected in 2018 (Company pipeline, AstraZeneca, 31 Dec
			2013 &amp; 31 Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^USA; a filing for use in patients with Type 2 diabetes and CAD but
			without previous history of MI or stroke (based on results from the
			THEMIS trial) is expected in 2018 (Press release, AstraZeneca, 30 Jul
			2015, Page 47,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285696919720&amp;ssbinary=true).
			^Acute coronary syndrome; Infarction, myocardial^China; a filing
			submission for use in patients with prior myocardial infarction
			(based on results from the PEGASUS-TIMI 54 trial) is expected in the
			2nd half of 2016 (Company pipeline, AstraZeneca, 31 Dec 2013 &amp; 31
			Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true;
			Company pipeline, AstraZeneca, 23 Feb 2016,
			https://www.astrazeneca.com/our-science/pipeline.html).^Japan; a
			filing has been accepted for acute coronary syndrome/post-myocardial
			infarction (3rd Qtr Res, AstraZeneca, 5 Nov 2015, Page 5 &amp; 22,
			https://www.astrazeneca.com/content/dam/az/our-company/investor-relations/presentations-and-webcast/AstraZeneca%20Results%20Presentation%20Q3%202015.pdf).
			A filing submission for use in patients with prior myocardial
			infarction (based on results from the PEGASUS-TIMI 54 trial) is
			expected in the 4th qtr of 2015 (Company pipeline, AstraZeneca, 31
			Dec 2013 &amp; 31 Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			Regulatory decisions for ACS and post-MI are expected in the 1st half
			of 2016 (Investor presentation, AstraZeneca, 4 Feb 2016, Slide 14,
			https://www.astrazeneca.com/content/dam/az/our-company/investor-relations/presentations-and-webcast/2016/Full-Year%20and%20Q4%202015%20Results%20presentation.pdf).^Acute
			coronary syndrome; Angina, unstable; Infarction, myocardial;
			Thrombosis, arterial^Albania; under regulatory review (Company
			presentation, AstraZeneca, 9 Sep 2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Argentina;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Bangladesh;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Behrain;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Bosnia
			and herzegovina; under regulatory review (Company presentation,
			AstraZeneca, 9 Sep 2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Brazil;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Chile;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Costa
			Rica; under regulatory review (Company presentation, AstraZeneca, 9
			Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Croatia;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Colombia;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Cuba;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Cyprus;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^El
			Salvodor; under regulatory review (Company presentation, AstraZeneca,
			9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Democratic
			Republic of Congo; under regulatory review (Company presentation,
			AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Ghana;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Guatemala;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Honduras;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Indonesia;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Israel;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Jamaica;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Jordon;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Kazakhstan;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Kuwait;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Mexico;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Montenegro;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Morocco;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Nicaragua;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Nigeria;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Panama;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Peru;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Philippines;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Russia;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 46,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).
			^Saudi Arabia; under regulatory review (Company presentation,
			AstraZeneca, 9 Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^South
			Africa; under regulatory review (Company presentation, AstraZeneca, 9
			Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Sri
			Lanka; under regulatory review (Company presentation, AstraZeneca, 9
			Sep 2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Sudan;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			^http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Thailand;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Turkey;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^UAE;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Ukraine;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Venezuela;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Yemen;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Zambia;
			under regulatory review (Company presentation, AstraZeneca, 9 Sep
			2011, page 49,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DInvestor-relations-general-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285628300321&amp;ssbinary=true).^Ischaemia,
			cerebral^China; filing for use in patients with stroke or TIA is
			expected in 2017 (Company pipeline, AstraZeneca, 31 Dec 2013 &amp; 31
			Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^EU; filing for use in patients with stroke or TIA is expected in the
			1st half of 2016 (Company pipeline, AstraZeneca, 31 Dec 2013 &amp; 31
			Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^Japan; filing for use in patients with stroke or TIA is expected in
			the 2nd half of 2016 (Company pipeline, AstraZeneca, 31 Dec 2013
			&amp; 31 Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^USA; filing for use in patients with stroke or TIA is expected in
			the 1st half of 2016 (Company pipeline, AstraZeneca, 31 Dec 2013
			&amp; 31 Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^Peripheral vascular disease^AstraZeneca^China; a filing for a line
			extension is expected in 2018 (Company pipeline, AstraZeneca, 31 Dec
			2013 &amp; 31 Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^EU; a filing for a line extension is expected in 2017 (Company
			pipeline, AstraZeneca, 31 Dec 2013 &amp; 31 Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^Japan; a filing for a line extension is expected in 2017 (Company
			pipeline, AstraZeneca, 31 Dec 2013 &amp; 31 Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^USA; a filing for a line extension is expected in 2017 (Company
			pipeline, AstraZeneca, 31 Dec 2013 &amp; 31 Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^Thrombosis, arterial^AstraZeneca^Japan; filed (Company pipeline,
			AstraZeneca, 30 Jun 2013 &amp; 31 Mar 2015, Page 28,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^Thrombosis, unspecified^EU; filing is expected in 2020 (Company
			pipeline, AstraZeneca, 31 Dec 2014, Page 36,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DPress-release-amp-development-pipeline.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285686741585&amp;ssbinary=true
			&amp; 31 Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^USA; filing is expected in 2020 (Company pipeline, AstraZeneca, 31
			Dec 2014, Page 36,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DPress-release-amp-development-pipeline.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285686741585&amp;ssbinary=true
			&amp; 31 Mar 2015, Page 34,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
			^Warnings^________________^USA; boxed warning states that maintenance
			doses of aspirin above 100mg reduce the effectiveness of ticagrelor,
			and should be avoided (Company presentation, AstraZeneca, 27 Jul
			2011, page 30,
			http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DPresentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285625738292&amp;ssbinary=true).
			^Expedited Review Designation^_________________^Acute coronary
			syndrome; Infarction, myocardial^USA; a priority review status has
			been granted for patients with a history of heart attack (Press
			release, AstraZeneca, 29 Apr 2015,
			http://www.astrazeneca.com/Media/Press-releases/Article/2015029--us-fda-grants-priroity-review-for-brilinta).
		</Marketing>
		<Licensing>Agreements^________________^The Medicines Company^USA;
			AstraZeneca has a 4yr collaboration agreement with the Medicines
			Company (TMC) for the copromotion of Brilinta. Under the agreement,
			the Medicines Company sales force will support Brilinta from May
			2012. The agreement is a first part of collaboration agreement with
			the Medicines Company in acute ischaemic heart disease (Press
			release, AstraZeneca, 25 Apr 2012,
			http://www.astrazeneca.com/Media/Press-releases/Article/20120425--astrazeneca-and-the-medicines-company).
		</Licensing>
		<KeyClinicalInformation>
			<PhaseIII>Acute coronary syndrome^It is in an event-driven,
				randomized, parallel-group, double-blind Phase III trial
				(D513BC00001; U1111-1149-3152; 2013-003519-23; THEMIS) in Argentina,
				Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China,
				Colombia, the Czech Republic, Denmark, Finland, France, Germany,
				Hungary, Hong Kong, India, Israel, Italy, Mexico, the Netherlands,
				Norway, Puerto Rico, Poland, Peru, the Philippines, Romania, Russia,
				Slovakia, S Korea, S Africa, Spain, Sweden, Taiwan, Thailand,
				Turkey, the UK, the US, Ukraine and Vietnam in 17000 patients with
				Type 2 diabetes at high risk of cardiovascular (CV) events to
				evaluate the efficacy of long-term treatment with ticagrelor 90mg po
				tablets bid vs placebo for the prevention of major CV events, the
				composite of CV death, MI or stroke (Press release, AstraZeneca, 14
				Nov 2013,
				http://www.astrazeneca-us.com/media/press-releases/Article/20131114-astrazeneca-announces-initiation-of-two-additional;
				ClinicalTrials.gov, 25 Nov 2013 &amp; 8 Nov 2014,
				http://clinicaltrials.gov/ct2/show/NCT01991795; Company pipeline,
				AstraZeneca, 31 Dec 2013 &amp; 31 Mar 2015, Page 34,
				http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
				Enrollment completion and trial completion are expected in 2018 (3rd
				Qtr Res, AstraZeneca, 5 Nov 2015, Page 14,
				https://www.astrazeneca.com/content/dam/az/our-company/investor-relations/presentations-and-webcast/AstraZeneca%20Clinical%20Trials%20Appendix%20Q3%202015%20Results.PDF;
				EU Clinical Trials Registry, 17 Dec 2015, 2013-003519-23,
				https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003519-23/HU).^In
				a randomized, double-blind, placebo-controlled, 3-arm,
				parallel-group Phase III trial (PEGASUS-TIMI 54, D5132C00001) in
				21412 patients on a background of ASA 75-150mg once-daily who have
				sustained a heart attack 1-3yr prior to enrollment in Argentina,
				Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China,
				Colombia, the Czech Republic, France, Germany, Hungary, India,
				Italy, Japan, the Netherlands, Norway, Peru, the Philippines,
				Poland, Romania, Russia, Slovakia, S Africa, S Korea, Spain, Sweden,
				Turkey, Ukraine, the UK and the US, top-line results showed that
				ticagrelor 60 or 90mg po bid x12mth met its primary efficacy
				endpoint. Preliminary analysis did not reveal any unexpected safety
				issues. Full evaluation of the data is ongoing. The primary efficacy
				endpoint was any event after randomization from the composite of
				cardiovascular death, non-fatal MI or non-fatal stroke within 1yr
				-38mth (Press release, AstraZeneca, 1 Oct 2010,
				http://www.astrazeneca.com/media/latest-press-releases/2010-new/PEGASUS?itemId=11566377;
				ClinicalTrials.gov, 9 Nov 2010 &amp; 24 Dec 2014,
				http://clinicaltrials.gov/ct2/show/NCT01225562; Press release,
				AstraZeneca, 14 Jan 2015,
				http://www.astrazeneca.com/Media/Press-releases/Article/20150114--PEGASUS-TIMI-54-study--BRILINTA-meets-primary-endpoint-in-60mg-and-90mg-doses).
				As of 14 Mar 2015, efficacy results showed that both 90mg and 60mg
				study doses of ticagrelor with aspirin significantly reduced the
				primary composite endpoint of cardiovascular (CV) death, myocardial
				infarction (MI) or stroke compared to placebo with 7.85% in the
				ticagrelor 90mg arm, 7.77% in the ticagrelor 60mg arm, and 9.04% in
				the placebo arm (Hazard Ratio (HR) for ticagrelor 90mg vs placebo
				0.85, 95% CI 0.75 ? 0.96; HR for ticagrelor 60mg vs placebo 0.84,
				95% CI 0.74 ? 0.95). The effect of ticagrelor on each of the
				components of the primary endpoint was consistent. A numerical
				decrease in the secondary endpoints of cardiovascular death and all
				cause mortality was observed, but did not reach statistical
				significance. In addition the primary efficacy endpoint of both
				doses of ticagrelor appeared consistent across major subgroups
				including age, sex, index MI type (STEMI/NSTEMI), time from
				qualifying MI, diabetes, aspirin dose, history of percutaneous
				intervention (angioplasty), and geographical region. Safety findings
				revealed that TIMI Major bleeding was higher in both doses of
				ticagrelor compared to placebo, with 2.60% in the ticagrelor 90mg
				arm, 2.30% in the ticagrelor 60mg arm and 1.06% in the placebo arm
				(HR for ticagrelor 90mg vs placebo 2.69, 95% CI 1.96 ? 3.70; HR for
				ticagrelor 60mg vs placebo 2.32, 95% CI 1.68 ? 3.21). The rates of
				fatal bleeding or intracranial haemorrhage were low and similar
				between treatment arms, with fatal bleeding rates at 3yr of 0.11% in
				the ticagrelor 90mg arm, 0.25% in the ticagrelor 60mg arm, and 0.26%
				in the placebo arm (HR for ticagrelor 90mg vs placebo 0.58, 95% CI
				0.22 ? 1.54; HR for ticagrelor 60mg vs placebo 1.00, 95% CI 0.44 ?
				2.27) and intracranial haemorrhage rates at 3yr of 0.56% in the
				ticagrelor 90mg arm, 0.61% in the ticagrelor 60mg arm and 0.47% in
				the placebo arm (HR for ticagrelor 90mg vs placebo 1.44, 95% CI 0.83
				? 2.49; HR for ticagrelor 60mg vs placebo 1.33, 95% CI 0.77 ?
				2.31).^In a worldwide (in countries as shown), randomized,
				double-blind Phase III trial (PLATO) in 18624 patients with acute
				coronary syndrome (ACS) (enrollment complete) to evaluate the safety
				and efficacy of ticagrelor 90mg bid + aspirin vs clopidogrel
				hydrogen sulfate 75mg once-daily (qv) + aspirin, ticagrelor met the
				primary efficacy endpoint of prevention of cardiovascular events
				without an increase in major bleeding. Further endpoints included
				first occurence of any event including myocardial infarction, stroke
				and CV death. Patients with stents experienced a 33% reduction in
				risk of definite stent thrombosis. There were no differences in
				major bleeding with ticagrelor vs clopidogrel. Further analysis of
				the PLATO trials in 1261 patients undergoing planned invasive
				treatments and with ST Segment Elevation Myocardial Infarction
				(STEMI), showed that ticagrelor reduced cardiovascular death,
				myocardial infarction, definite stent thrombosis and total mortality
				cf clopidogrel (Analysts&apos; presentation, AstraZeneca, 2 Feb
				2006; 2nd Qtr Res, AstraZeneca, 2008 &amp; 2009; ClinicalTrials.gov
				Web Page, 18 Aug 2008, NCT00391872; Press releases, AstraZeneca, 11
				May, 31 Aug, 25 Sep &amp; 16 Nov 2009; Scrip Daily Online, 11 May
				2009, S01027064).^ In a PLATO sub-analysis, ticagrelor showed a
				reduction of total mortality by 51% and CV death by 48% when
				adminstered to ACS patients 7 days prior to having a coronary artery
				bypass graft (CABG) vs clopidogrel (Press release, AstraZeneca, 16
				Mar 2010). In 54 patients treated with ticagrelor instead of
				clopidogrel for 1yr, it prevented one atherothrombotic event and
				treating 91 patients prevented one cardiovascular death, with no
				increase in overall major/fatal bleeding over the course of one year
				of treatment (11.6% for ticagrelor vs 11.2% for clopidogrel) (Press
				release, AstraZeneca, 6 Dec 2010,
				http://www.astrazeneca.com/Media/Press-releases/Article/European-Commission-Approves-Brilique).
				Total rates of vascular deaths and non-vascular deaths from the time
				of CABG until study end for the ticagrelor and clopidogrel groups
				were 4, 0.6% and 7.5, 1.7%, respectively. Ticagrelor reduced
				definite stent thrombosis compared with clopidogrel, independent of
				type of ACS, diabetes status, stent type, loading dose of aspirin
				and dose of clopidogrel pre-randomisation. Fewer
				cardiovascular-related deaths from heart attack, heart failure,
				arrhythmia/sudden death, haemorrhagic stroke/intracranial
				haemorrhage and bleeding/other haemorrhage were observed (Press
				release, AstraZeneca, 30 Aug 2011,
				http://www.biospace.com/News/astrazeneca-plc-bloodthinner-shows-mortality/231556/source=TopBreaking).
				A sub-analysis that evaluated the effect of smoking status on
				clinical outcomes in patients with acute coronary syndrome (ACS)
				suggested the overall findings from the PLATO study of greater
				reduction in thrombotic CV events with ticagrelor tablets + aspirin
				compared to clopidogrel + aspirin was consistent regardless of
				smoking habits. Among the 18610 patients with known smoking status
				at randomization in the PLATO study, 6678 (36%) were reported as
				being habitual smokers and 11932 (64%) were ex/non-smokers. Habitual
				smokers had an overall lower risk profile and presented more often
				with ST-elevation MI. After adjustment for baseline differences,
				habitual smoking was associated with a higher incidence of definite
				stent thrombosis; there were no significant associations with other
				ischaemic or bleeding end points. The effects of ticagrelor compared
				to clopidogrel were consistent for thrombotic CV events, regardless
				of smoking status. Thus, there was a similar reduction in the
				primary composite end point for habitual smokers and ex/non-smokers,
				and in definite stent thrombosis for habitual smokers and
				ex/non-smokers. There was no significant interaction between smoking
				habits and the effects of treatment on major bleeding or non-CABG
				related major bleeding. The adjusted hazard ratios for the rate of
				all PLATO-defined major bleeding for ticagrelor versus clopidogrel
				were 1.18 in habitual smokers and 1.04 in ex/non-smokers. For
				non-CABG related major bleeding events the adjusted hazard ratios
				for ticagrelor versus clopidogrel were 1.22 in habitual smokers and
				1.35 in ex/non-smokers. The conclusion of the sub-analysis of PLATO
				suggested results of ticagrelor versus clopidogrel were consistent
				for thrombotic cardiovascular (CV) events in patients with ACS
				regardless of smoking status and that habitual smoking was
				associated with a greater risk of subsequent stent thrombosis (Press
				release, AstraZeneca, 6 Sep 2012,
				http://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&amp;newsId=20120906006378&amp;newsLang=en).^A
				randomized, double-blind, parallel-assignment, double-dummy Phase
				III trial (D5130C00027; PHILO) to evaluate the safety and efficacy
				of ticagrelor 90mg po bid vs clopidogrel 75mg po once-daily on top
				of low dose ASA in 800 patients with non-ST or ST elevation ACS with
				planned percutaneous coronary intervention (PCI) in Japan, S Korea
				and Taiwan was completed (ClinicalTrials.gov, 28 Mar 2011and 25 Aug
				2012, http://www.clinicaltrials.gov/show/NCT01294462; Press release,
				AstraZeneca, 17 Jul 2012,
				http://www.biospace.com/News/astrazeneca-plc-starts-new-study-of-heart-drug/266902/source=TopBreaking).^Peripheral
				vascular disease^It is in a randomized, double-blind, parallel-group
				Phase IIIb trial (EUCLID) in 13500 patients (enrollment complete)
				aged 50yr or older with peripheral artery disease (PAD) in
				Argentina, Brazil, Bulgaria, Canada, Chile, China, the Czech
				Republic, France, Germany, Hungary, Italy, Japan, Mexico, the
				Netherlands, the Philippines, Poland, Romania, Russia, Slovakia, S
				Africa, S Korea, Spain, Sweden, Thailand, Turkey, Ukraine, the UK,
				the US and Vietnam, to evaluate the efficacy and safety of
				ticagrelor 90mg po bid against clopidogrel 75mg po once-daily in
				reducing a composite of CV death, MI or ischaemic stroke in patients
				with PAD (Press release, AstraZeneca, 17 Jul 2012,
				http://www.biospace.com/News/astrazeneca-plc-starts-new-study-of-heart-drug/266902/source=TopBreaking;
				ClinicalTrials.gov, 26 Dec 2012 &amp; 8 Nov 2014,
				http://clinicaltrials.gov/ct2/show/NCT01732822; Company pipeline,
				AstraZeneca, 30 Jun 2012 &amp; 31 Mar 2015, Page 34,
				http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
				Data is expected in the 2nd half of 2016 (3rd Qtr Res, AstraZeneca,
				5 Nov 2015, Page 24,
				https://www.astrazeneca.com/content/dam/az/our-company/investor-relations/presentations-and-webcast/AstraZeneca%20Results%20Presentation%20Q3%202015.pdf).
				Enrollment completion is expected in the 2nd half of 2016 (3rd Qtr
				Res, AstraZeneca, 5 Nov 2015, Page 14,
				https://www.astrazeneca.com/content/dam/az/our-company/investor-relations/presentations-and-webcast/AstraZeneca%20Clinical%20Trials%20Appendix%20Q3%202015%20Results.PDF).^Thrombosis,
				unspecified^A randomized, open-label, crossover Phase III trial
				(D5130C00078) to evaluate the safety and P2Y12 receptor inhibition
				effects of ticagrelor 90mg x5 days and clopidogrel in Vietnamese
				patients in Vietnam with coronary heart disease has been withdrawn
				prior to enrollment (ClinicalTrials.gov, 29 Dec 2012 &amp; 15 May
				2013, http://clinicaltrials.gov/ct2/show/NCT01757262). ^In a 6wk,
				randomized, double-blind clinical trial (ONSET/OFFSET) in 123
				patients on stable coronary artery disease (CAD) therapy, ticagrelor
				90mg bid achieved a rapid onset of antiplatelet activity, inhibition
				of platelet aggregation and faster offset IPA cf clopidogrel (Press
				release, AstraZeneca, 18 Nov 2009).^Ischaemia,
				cerebral^AstraZeneca^It is in a randomized, double-blind,
				parallel-group Phase III study (SOCRATES) in 13600 patients
				(enrollment complete) who have experienced an acute ischaemic stroke
				or transient ischaemic attack (TIA) in Argentina, Australia,
				Belgium, Brazil, Bulgaria, Canada, Chile, China, the Czech Republic,
				France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Mexico,
				Peru, the Philippines, Poland, Romania, Russia, Slovakia, S Korea,
				Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine,
				Vietnam and the US, to evaluate the efficacy of ticagrelor 90mg po
				tablets bid vs aspirin in reducing major vascular events (composite
				of all-cause mortality, myocardial infarction and stroke).
				Completion is expected in Oct 2015 (Press release, AstraZeneca, 14
				Nov 2013,
				http://www.astrazeneca-us.com/media/press-releases/Article/20131114-astrazeneca-announces-initiation-of-two-additional;
				ClinicalTrials.gov, 3 Dec 2013, 8 Nov 2014 &amp; 22 Dec 2015,
				http://clinicaltrials.gov/ct2/show/NCT01994720; EU Clinical Trials
				Register, 2012-003895-38, 9 Oct 2015,
				https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003895-38;
				Company pipeline, AstraZeneca, 31 Dec 2013 &amp; 31 Mar 2015, Page
				34,
				http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
				Data is expected in the 1st half of 2016 (1st Half Res, AstraZeneca,
				30 Jul 2015, Page 11,
				http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-presentation.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285696934628&amp;ssbinary=true;
				3rd Qtr Res, AstraZeneca, 5 Nov 2015, Page 14,
				https://www.astrazeneca.com/content/dam/az/our-company/investor-relations/presentations-and-webcast/AstraZeneca%20Clinical%20Trials%20Appendix%20Q3%202015%20Results.PDF).
			</PhaseIII>
			<PhaseII>Peripheral vascular disease^It is in a multicentre,
				randomized, double-blind, controlled, parallel-group Phase II trial
				(D5135L00003, TI-PAD EVR) in the US to evaluate the walking time
				effect of long-term ticagrelor 90mg bid in comparison to long-term
				aspirin administration in 175 ambulatory patients (enrollment
				complete) with peripheral artery disease undergoing endovascular
				revascularization (ClinicalTrials.gov, 6 Nov 2014 &amp; 23 Dec 2015,
				http://clinicaltrials.gov/ct2/show/NCT02227368). ^Thrombosis,
				unspecified^It is in a randomized, double-blind, double-dummy,
				parallel-group Phase IIb trial (D5136C00008), to evaluate the effect
				of ticagrelor 10 and 45mg bid versus placebo in reducing the number
				of days with pain in 90 young adults with sickle cell disease
				(ClinicalTrials.gov, 29 Jun 2015,
				https://clinicaltrials.gov/show/NCT02482298).^An open-label,
				randomized, dose-ranging Phase II trial (D5136C00007, HESTIA 1) in
				Canada, S Africa, the UK and the US to evaluate the pharmacokinetics
				and pharmacodynamics of ticagrelor followed by a double-blind,
				randomized, parallel-group, placebo-controlled, 4wk extension Phase
				in 39 paediatric patients with sickle cell disease has suspended
				participant recruitment (ClinicalTrials.gov, 25 Sep 2014 &amp; 16
				Oct 2015, http://clinicaltrials.gov/ct2/show/NCT02214121; Company
				pipeline, AstraZeneca, 31 Dec 2014, Page 36,
				http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DPress-release-amp-development-pipeline.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285686741585&amp;ssbinary=true
				&amp; 31 Mar 2015, Page 34,
				http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&amp;blobheader=application%2Fpdf&amp;blobheadername1=Content-Disposition&amp;blobheadername2=MDT-Type&amp;blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&amp;blobheadervalue2=abinary%3B+charset%3DUTF-8&amp;blobkey=id&amp;blobtable=MungoBlobs&amp;blobwhere=1285691535910&amp;ssbinary=true).
				^A randomized, double-blind, parallel-group Phase II (D5130C00065)
				trial to evaluate the pharmacokinetic (PK) and pharmacodynamic
				profile of 2 doses of ticagrelor x4wk vs clopidogrel on top of low
				dose ASA on platelet aggregation in 146 patients with stable
				coronary artery disease in Japan and Philippines was completed
				(ClinicalTrials.gov, 18 Feb 2011,
				http://clinicaltrials.gov/ct2/show/NCT01118325). ^A randomized,
				double-blind, parallel-assignment Phase II trial in 80 patients with
				stable CAD to assess ticagrelor po vs clopidogrel hydrogen sulfate
				on the primary endpoint of inhibition of platelet aggregation in
				non-responders to clopidogrel hydrogen sulfate was completed.
				Secondary endpoints include inhibition of platelet aggregation and
				biomarker expression in clopidogrel hydrogen sulfate responsive
				patients (ClinicalTrials.gov Web Page, 23 May 2008 &amp; 15 Mar
				2010, NCT00642811). ^In a randomized Phase II trial (RESPOND),
				ticagrelor increased mean IPA by 26% in CAD patients who were
				switched from clopidogrel to ticagrelor vs a 24% decrease when
				switched from ticagrelor to clopidogrel. Results for the primary
				endpoint in clopidogrel non-responders were not significant (Press
				release, AstraZeneca, 18 Nov 2009).^In Phase II trials, it showed
				faster and more complete platelet inhibition cf clopidogrel hydrogen
				sulfate, and total bleeding was similar to clopidogrel hydrogen
				sulfate. It was generaly well tolerated (Analysts&apos;
				presentation, AstraZeneca, 2 Feb 2006). ^A Phase II trial (DISPERSE)
				compared the ability of ticagrelor to inhibit platelet aggregation
				with clopidogrel hydrogen sulfate(Press release, AstraZeneca, 15 Nov
				2005).^In a Phase IIb trial (DISPERSE2), ticagrelor + ASA 90mg bid,
				180mg bid and 75mg/day gave an overall incidence of total bleeding
				events of 10.2, 10.2 and 9.2%, respectively, with major bleeds in
				7.8 and 6.2% in the 90 bid and 180mg bid groups, respectively, cf 8%
				with clopidrogrel hydrogen sulfate 75mg (Press release, AstraZeneca,
				15 Nov 2005). The 90mg bid dose has been selected for further trials
				(Analysts&apos; presentation, AstraZeneca, 1 Feb 2007).</PhaseII>
			<PhaseI>AstraZeneca^An open-label, randomized, 3-period, 3-treatment,
				crossover, single-centre, single-dose Phase I trial (D5139C00004) in
				the UK to assess the bioequivalence between ticagrelor 90mg
				orodispersible tablets and ticagrelor IR tablets in 42 healthy
				Japanese subjects, is complete (ClinicalTrials.gov, 8 May, 15 Jun
				&amp; 31 Aug 2015 &amp; 11 Sep 2015,
				https://www.clinicaltrials.gov/ct2/show/NCT02436577). Top-line
				results are expected in the 4th qtr of 2015 (3rd Qtr Res,
				AstraZeneca, 5 Nov 2015, Page 14,
				https://www.astrazeneca.com/content/dam/az/our-company/investor-relations/presentations-and-webcast/AstraZeneca%20Clinical%20Trials%20Appendix%20Q3%202015%20Results.PDF).^An
				open-label, randomized, 4-period, 4-treatment, crossover,
				single-dose Phase I trial (D5139C00003) in Germany to evaluate the
				bioavailability of ticagrelor orodispersible tablets (ODT)
				administered with water, without water and suspended in water to be
				administered through nasogastric tubes vs ticagrelor IR tablets in
				36 healthy subjects (enrollment complete) (ClinicalTrials.gov, 3 Apr
				2015, 18 Jun 2015, 8 Jul &amp; 10 Aug 2015,
				https://www.clinicaltrials.gov/ct2/show/NCT02400333). Top-line
				results are expected in the 4th qtr of 2015 (3rd Qtr Res,
				AstraZeneca, 5 Nov 2015, Page 14,
				https://www.astrazeneca.com/content/dam/az/our-company/investor-relations/presentations-and-webcast/AstraZeneca%20Clinical%20Trials%20Appendix%20Q3%202015%20Results.PDF)^An
				open-label, randomized, crossover and potential parallel,
				single-dose Phase I trial (D5130C00079) of ticagrelor 180mg and
				acetylsalicylic acid in 258 healthy volunteers followed by
				autologous in-vivo platelet transfusion to determine the effects of
				platelet supplementation on the reversibility of platelet inhibition
				in the US, is complete (ClinicalTrials.gov, 10 Dec 2012 &amp; 25 Apr
				2014, http://clinicaltrials.gov/ct2/show/study/NCT01744288). ^It is
				in an open-label, randomized, cross-over assignment, single-dose,
				parallel-group Phase I trial (D5130L00067) in 40 hemodialysis
				patients and healthy subjects with normal renal function in the US,
				to compare the pharmacokinetics, pharmacodynamics, safety and
				tolerability of ticagrelor 90mg po tablet (ClinicalTrials.gov, 20
				Feb 2014, http://clinicaltrials.gov/ct2/show/NCT02022748). ^An
				open-label, randomized, 3-period, 3-treatment, crossover,
				single-dose Phase I trial (D5130C00076) to investigate the
				bioavailability of ticagrelor 90mg po crushed tablets or when
				administered through nasogastric tubes vs whole tablets in 36
				healthy volunteers in India, the UK and the US, is complete
				(ClinicalTrials.gov, 11 Jul &amp; 20 Sep 2013,
				http://www.clinicaltrials.gov/show/NCT01887626). ^An open-label
				Phase I trial (D5133C00001) to assess the pharmacokinetics of
				single-dose ticagrelor 90mg po tablet in 12 healthy Japanese male
				volunteers in Japan was completed (ClinicalTrials.gov, 25 May 2012
				and 16 Jul 2012, http://clinicaltrials.gov/ct2/show/NCT01588626).
				^An open-label, randomized, 3-treatment, 3-period cross-over Phase I
				trial (D5130C00074) to assess the effect of cyclosporine 600mg on
				the pharmacokinetics, safety, and tolerability of single-dose
				ticagrelor 180mg po tablet and the effect of ticagrelor on the
				pharmacokinetics, safety, and tolerability of cyclosporine in 20
				healthy male subjects in the US was completed (ClinicalTrials.gov,
				27 Jan 2012 and 10 Jul 2012,
				http://clinicaltrials.gov/ct2/show/NCT01504906). ^A sequential,
				open-label, crossover-assignment Phase I trial (D5130C00073) to
				evaluate the drug-drug interaction and to compare the PK, safety and
				tolerability of single-dose ticagrelor 90mg po immediate release
				(IR) tablets on day 1 and 9 and venlafaxine 37.5mg po bid given
				concomitantly in 22 healthy subjects aged 18 to 45 yr in Sweden and
				the US was completed (ClinicalTrials.gov, 11 May 2011 and 2 Apr
				2012, http://www.clinicaltrials.gov/show/NCT01350921). ^A
				randomized, double-blind, placebo-controlled, crossover Phase I
				trial (D5130C00067) to evaluate the effect of ticagrelor 180mg on
				adenosine-induced coronary blood flow velocity in 39 healthy male
				subjects in Sweden was completed (ClinicalTrials.gov, 22 Apr 2011,
				http://clinicaltrials.gov/ct2/show/NCT01226602). ^Thrombosis,
				unspecified^In a single-dose-escalating trial in healthy volunteers,
				ticagrelor showed maximal platelet inhibition 2hr post dose, and
				inhibition continued x24hr. In a steady-state trial in healthy
				volunteers, ticagrelor resulted in greater antiplatelet effect and
				lower variability cf clopidogrel hydrogen sulfate (Ann Bus Rev,
				AstraZeneca, 6 Oct 2004).</PhaseI>
			<Preclinical>In vivo^It had 40 and 86% bioavailability in rats and
				dogs, respectively (225th ACS (New Orleans), 2003, MEDI 16).^In
				preclinical studies, ticagrelor 200mg produced more consistent and
				complete inhibition of ADP-induced platelet aggregation vs a loading
				dose of 300mg clopidogrel hydrogen sulfate (Ann Bus Rev,
				AstraZeneca, 7 Nov 2002).</Preclinical>
		</KeyClinicalInformation>
	</CASIS.TX>
	<LatestChangeDate>20160223</LatestChangeDate>
	<LatestChange>Revised timing of Chinese filing for myocardial
		infarction, acute coronary syndrome and the EU approval for myocardial
		infarction reported</LatestChange>
	<CASIS.RDAT>
		<KeyEvent>20131114 New Therapeutic Activity:Neuroprotective</KeyEvent>
		<KeyEvent>20131114 New Disease:Ischaemia, cerebral</KeyEvent>
		<KeyEvent>20121221 Change in Disease Status:Peripheral vascular
			disease; Phase III Clinical Trial</KeyEvent>
		<KeyEvent>20121129 Additional Registrations:China; Acute coronary
			syndrome; Thrombosis, arterial</KeyEvent>
		<KeyEvent>20121019 Additional Launches:India; Acute coronary syndrome
		</KeyEvent>
		<KeyEvent>20120815 Additional Launches:Australia; Various indications
		</KeyEvent>
		<KeyEvent>20120726 Additional Launches:Italy; Various indications
		</KeyEvent>
		<KeyEvent>20120717 New Disease:Peripheral vascular disease</KeyEvent>
		<KeyEvent>20120715 Additional Launches:France; Acute coronary syndrome
		</KeyEvent>
		<KeyEvent>20120425 New Licensees:The Medicines Company; The US
		</KeyEvent>
		<KeyEvent>20110909 Additional Registrations:Various countries
		</KeyEvent>
		<KeyEvent>20110909 Additional Launches:Various countries</KeyEvent>
		<KeyEvent>20110822 Additional Launches:The US</KeyEvent>
		<KeyEvent>20110815 Additional Registrations:New Zealand</KeyEvent>
		<KeyEvent>20110720 Additional Registrations:The US</KeyEvent>
		<KeyEvent>20110720 Additional Registrations:Australia</KeyEvent>
		<KeyEvent>20110601 Additional Registrations:Canada</KeyEvent>
		<KeyEvent>20110127 Additional Registrations:Norway</KeyEvent>
		<KeyEvent>20110127 Additional Registrations:Iceland</KeyEvent>
		<KeyEvent>20110127 Additional Registrations:Brazil</KeyEvent>
		<KeyEvent>20110127 Additional Launches:Germany</KeyEvent>
		<KeyEvent>20110127 Additional Launches:Denmark</KeyEvent>
		<KeyEvent>20110104 First Launches:The UK, NAS</KeyEvent>
		<KeyEvent>20101206 First Registrations:The EU</KeyEvent>
		<KeyEvent>20091026 Registration Submissions:The EU</KeyEvent>
		<KeyEvent>20070823 New Chemical Structure:New</KeyEvent>
		<KeyEvent>20070821 Names Granted:AZD-6140</KeyEvent>
		<KeyEvent>20060202 Change in Global Status:Phase III Clinical Trial
		</KeyEvent>
		<KeyEvent>20031002 Change in Global Status:Phase II Clinical Trial
		</KeyEvent>
		<KeyEvent>20010726 Compounds Identified:P2X7 antagonists, AstraZeneca
		</KeyEvent>
		<KeyEvent>20010726 Change in Global Status:Phase I Clinical Trial
		</KeyEvent>
		<KeyEvent>20010407 New Product</KeyEvent>
	</CASIS.RDAT>
	<CASIS.DSTA>
		<Country>World: Launched</Country>
		<Country>AR: Pre-registration; Licensing Availability: Unknown
		</Country>
		<Country>AU: Launched 2012; Licensing Availability: Unknown</Country>
		<Country>AT: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>BE: Registered; Licensing Availability: Unknown</Country>
		<Country>BR: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>CA: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>CL: Pre-registration; Licensing Availability: Unknown
		</Country>
		<Country>CN: Launched; Licensing Availability: Unknown</Country>
		<Country>CO: Pre-registration; Licensing Availability: Unknown
		</Country>
		<Country>DK: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>SF: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>FR: Launched 2012; Licensing Availability: Unknown</Country>
		<Country>DE: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>GR: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>HK: Phase III Clinical Trial; Licensing Availability: Unknown
		</Country>
		<Country>IN: Launched 2012; Licensing Availability: Unknown</Country>
		<Country>IE: Registered; Licensing Availability: Unknown</Country>
		<Country>IL: Phase III Clinical Trial; Licensing Availability: Unknown
		</Country>
		<Country>IT: Launched 2012; Licensing Availability: Unknown</Country>
		<Country>JP: Pre-registration; Licensing Availability: Unknown
		</Country>
		<Country>LU: Registered; Licensing Availability: Unknown</Country>
		<Country>MY: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>MX: Pre-registration; Licensing Availability: Unknown
		</Country>
		<Country>NL: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>NZ: Registered; Licensing Availability: Unknown</Country>
		<Country>NO: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>PE: Pre-registration; Licensing Availability: Unknown
		</Country>
		<Country>PH: Phase III Clinical Trial; Licensing Availability: Unknown
		</Country>
		<Country>PT: Registered; Licensing Availability: Unknown</Country>
		<Country>RU: Pre-registration; Licensing Availability: Unknown
		</Country>
		<Country>ZA: Pre-registration; Licensing Availability: Unknown
		</Country>
		<Country>KR: Registered; Licensing Availability: Unknown</Country>
		<Country>ES: Registered; Licensing Availability: Unknown</Country>
		<Country>SE: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>CH: Phase III Clinical Trial; Licensing Availability: Unknown
		</Country>
		<Country>TH: Pre-registration; Licensing Availability: Unknown
		</Country>
		<Country>TR: Pre-registration; Licensing Availability: Unknown
		</Country>
		<Country>UK: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>US: Launched 2011; Licensing Availability: Unknown</Country>
		<Country>VE: Pre-registration; Licensing Availability: Unknown
		</Country>
	</CASIS.DSTA>
	<CASIS.CO>
		<Company>Originator: AstraZeneca: Launched</Company>
		<Company>Licensee: The Medicines Company: Launched</Company>
	</CASIS.CO>
	<CASIS.LN>
		<LN>Antithrombotic, other:Launched</LN>
		<LN>Cardiovascular:Launched</LN>
		<LN>Neuroprotective:Launched</LN>
	</CASIS.LN>
	<CASIS.USE>
		<CASIS.ACT>
			<ACT>Antithrombotic, other</ACT>
			<ACT>Cardiovascular</ACT>
			<ACT>Neuroprotective</ACT>
		</CASIS.ACT>
		<CASIS.MA>
			<MA>Purinoreceptor P2Y12 antagonist</MA>
		</CASIS.MA>
		<CASIS.IND>
			<IND>Acute coronary syndrome::Launched</IND>
			<IND>Angina, unstable::Launched</IND>
			<IND>Coronary artery bypass grafting::Launched</IND>
			<IND>Infarction, myocardial::Launched</IND>
			<IND>Ischaemia, cerebral::Phase III Clinical Trial</IND>
			<IND>Peripheral vascular disease::Phase III Clinical Trial</IND>
			<IND>Thrombosis, arterial::Launched</IND>
			<IND>Thrombosis, unspecified::Phase II Clinical Trial</IND>
		</CASIS.IND>
	</CASIS.USE>
	<DeliveryData>
		<DeliveryRouteData>
			<DeliveryRoute>Oral</DeliveryRoute>
			<DeliveryRoute>Oral, swallowed</DeliveryRoute>
		</DeliveryRouteData>
		<DeliveryMediumData>
			<DeliveryMedium>Tablet</DeliveryMedium>
		</DeliveryMediumData>
		<DeliveryTechnologyData>
			<DeliveryTechnology>Immediate-release</DeliveryTechnology>
			<DeliveryTechnology>Rapidly-disintegrating</DeliveryTechnology>
		</DeliveryTechnologyData>
	</DeliveryData>
	<TargetData>
		<Targets>
			<Target>
				<TargetName>purinergic receptor P2Y, G-protein-coupled, 12
				</TargetName>
				<EntrezGeneID>64805</EntrezGeneID>
				<TargetTarget>
					<TargetTargetFamilies>
						<TargetTargetFamily>Receptor &gt; GPCR &gt; P2Y
						</TargetTargetFamily>
					</TargetTargetFamilies>
				</TargetTarget>
			</Target>
		</Targets>
	</TargetData>
	<DrugURL>http://bayer-pipeline.citeline.com/CpViewAccess.aspx?B=25950&amp;C=0&amp;D=9
	</DrugURL>
	<CASIS.MDNUMBER>MD000001</CASIS.MDNUMBER>
</Document>